Evogene to Detail AI Drug Discovery Advances at BIO-Europe Spring
Event summary
- Evogene will present at BIO-Europe Spring 2026 in Lisbon, Portugal, from March 23-25, 2026.
- Dr. Olga Nissan, VP Business Development, will deliver an oral presentation on March 24, 2026, at 15:30 WET.
- The presentation will focus on advancements in Evogene’s AI-driven small-molecule discovery and optimization using ChemPass AI™.
- Dr. Gabi Tarcic, Chief Development Officer, and Dr. Nissan will be available for one-on-one meetings.
The big picture
Evogene's focus on generative AI for drug discovery aligns with the broader trend of leveraging artificial intelligence to accelerate pharmaceutical R&D and reduce costs. The company's reliance on ChemPass AI™ positions it within a competitive landscape of computational chemistry firms, and its ability to secure partnerships and demonstrate tangible results will be critical for long-term viability. The company's exposure to geopolitical risk in the Middle East adds a layer of complexity to its investment profile.
What we're watching
- Partnerships
- The success of Evogene's collaborative drug discovery model hinges on securing and retaining partnerships with established pharmaceutical and biotech firms, and the conference provides a key opportunity to assess the progress of those relationships.
- Geopolitical Risk
- The company's forward-looking statements explicitly mention the ongoing geopolitical instability in the Middle East, which could significantly disrupt operations and supply chains, and will be a key factor in investor sentiment.
- ChemPass AI
- The efficacy of ChemPass AI™ in consistently generating viable drug candidates will dictate Evogene’s ability to move beyond early-stage development and achieve commercial success, and the conference presentation will offer insights into its performance.
Related topics